To useourproprietaryLDL technologytocreatenewchemotherapeuticsthat selectivelytargettumorsandtherebyimprovetolerabilityandefficacyof knownmoleculesaswellasenablenovelones.


To use our proprietary LDL technology to create new chemotherapeutics that selectively target tumors and thereby improve tolerability and efficacy of known molecules as well as enable novel ones.

Cloaked Therapeutics, LLC is a private biopharmaceutical limited liability company registered in Delaware and located near Oxford, Mississippi.  Cloaked was formed in 2014 to commercially develop, under exclusive license, proprietary TumorSelect® technology discovered by Veiled Therapeutics, LLC.

The company’s proprietary TumorSelect® technology selectively delivers active anticancer agents into tumor cells.  Pseudo-LDL particles containing novel prodrugs of clinically approved chemotherapeutic agents are used to improve the selective uptake of cytotoxics by tumors in order to improve efficacy and reduce toxicity. This technology is well established both preclinically and clinically.

Cloaked has used TumorSelect® to create an exciting proof-of-concept lead program with an advanced delivery system for paclitaxel that promises to improve both its efficacy and tolerability when compared with standard Cremophor® as well as newer Abraxane® formulations.


TumorSelect® mechanism of action has potential indications for enhanced safety and efficacy of therapy by selective delivery to tumor tissues including the cancers:

  • ​Breast
  • Colorectal
  • Gastric
  • Glioblastoma
  • Leukemia
  • Melanoma
  • Non-small cell lung
  • Ovarian
  • Pancreatic
  • Prostate


Each of the founding technical members of Cloaked Therapeutics is a recognized and experienced leader in drug discovery and development.

James D. McChesney, Ph.D. has more than 50 years of experience in natural products chemistry and more than 25 years of experience in drug discovery and development. He conceived and implemented the National Center for Natural Products Research on the Ole Miss campus; developed an economic commercial process for paclitaxel production from cultivated Taxus biomass; and designed and developed a next generation taxane (TPI 287) currently in Phase II clinical trials.
Steve J. Bannister, Ph.D. has 30 years of experience applying the fundamentals of physical and analytical chemistry to the design, development, and characterization of drug delivery systems.
Lisa McChesney-Harris, Ph.D. is formally trained in pharmaceutical chemistry and has over 22 years of experience spanning every aspect of pharmaceutical drug development, from preformulation through A/NDA submission and FDA interactions.
Sam L. Nguyen, Ph.D., JD, has over 15 years of pharmaceutical research with international pharmaceutical companies and over 15 years of practice as a patent attorney.
Jonas V. Alsenas, DVM, who serves as our strategic consultant has over 25 years of experience as a biotechnology industry analyst, executive and consultant.
Michael A Hawotte, President of The Staghorn Group, Inc., a Management Consulting and Forensic Investigations company.


James O. McCash, Investor, is a former owner and executive, of a national contracting firm and has been committed to the research and development of new therapies for the treatment of various types of cancer.
Cheryl A. London, DVM, Ph.D., is the current Director of the Clinical Trials Office at the Cummings School of Veterinary Medicine at Tufts University. She is a veterinary medical oncologist with over 20 years of experience in the fields of translational and comparative oncology and drug development.
Jinhui Dou, Ph.D. After receiving his BS (Pharmacy) and MS (Pharmacognosy) degrees, Jinhui Dou became a faculty member at Beijing University of Chinese Medicine and taught pharmacy classes for 4 years. He accepted a graduate assistantship from the Pharmacognosy Department at the University of Mississippi and received a PhD degree in 1996 from Dr. James McChesney, a distinguished professor of pharmacognosy. After working at the University of Kansas as a post-doc associate, he became a Natural Product Scientist at NaPro BioTherapeutics in December 1996. He led a group of chemists and engineers in the reduction of paclitaxel manufacturing costs and in the establishment of a library of related-substance reference standards to support the CMC, pharmacology, and toxicology sections of paclitaxel NDA and ANDA filings. Dr. Dou joined the FDA in 2002 as a pharmacologist reviewer in the Center for Drug Evaluation and Research (CDER). He reviewed anti-infective and anti-inflammatory chemical-drug filings for several years before working as a botanical reviewer full time. He was a CDER and Agency expert pharmacologist and pharmacognosist specialized in botanical drug review. Dr. Dou received numerous awards from CDER, FDA, and HHS for his distinguished contributions to the development of new guidances, policies, and regulations and his scientific reviews of new botanical and chemical drugs. After more than 15 years at FDA, Dr. Dou, in 2017, joined Yiling Pharmaceutical, headquartered in Shijiazhuang, China, as a Vice Dean of the Yiling Research Institute. He now works as a pharmacology and pharmacognosy consultant for the pharmaceutical industry worldwide. Dr. Dou is a member of American Society of Pharmacognosy (ASP) and the NIH/NCI PDQ Integrative, Alternative, and Complementary Therapies (IACT) editorial board. His publications on lupin alkaloids, green tea, quassinoinds, and proanthocyanidins are from his research activities or new drug review experience.